Blister fluid composition in a pediatric patient with toxic epidermal necrolysis

Journal of Burn Care and Research

Volumn 29, Issue 4, 2008, Pages 671-675

  Gandhi, Mona ^a   Vern, Areta Kowal ^a   An, Gary ^b   Hanumadass, Marella ^a  

^a Jr Hospital of Cook County   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCIUM; CARBAMAZEPINE; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; MAGNESIUM; MINERAL; PHENOBARBITAL; ALBUMINOID; ANTICONVULSIVE AGENT; PROTEIN;

ARTICLE; BLISTER; BURN; CASE REPORT; CHILD; DEBRIDEMENT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; IMMUNOFLUORESCENCE; MALE; PAIN; SCHOOL CHILD; SEIZURE; SKIN BIOPSY; SKIN GRAFT; TOXIC EPIDERMAL NECROLYSIS; WOUND CARE; XENOGRAFT; COMPARATIVE STUDY; EPILEPSY; METABOLISM;

ALBUMINS; ANTICONVULSANTS; BLISTER; BURNS; CALCIUM; CARBAMAZEPINE; CHILD; EPIDERMAL NECROLYSIS, TOXIC; EPILEPSY; HUMANS; IMMUNOGLOBULINS; L-LACTATE DEHYDROGENASE; MAGNESIUM; MALE; PROTEINS;

EID: 56149105717     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e31817db8c8     Document Type: Article

References (21)

1. Spies M, Sanford AP, Aili Low JF, Wolf S, Herndon DN. Treatment of extensive toxic epidermal necrolysis in children. Pediatrics 2001;108:1162-1168.
2. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956;68:355-361.
3. Roujeau JC, Stern RS. Severe adverse cutaneous reaction to drugs. N Engl J Med 1994;331:1272-1284.
4. Ducic I, Shalom A, Rising W, Nagamoto K, Munster A. Outcome of patients with toxic epidermal necrolysis syndrome revisited. Plast Reconstr Surg 2002;110:768-773.
5. Tristani-Firouzi P, Petersen MJ, Saffle JR, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002;47:548-552.
6. Schulz JT, Sheridan RL, Ryan CM, MacKool B, Tompkins RG. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000;21:199-204.
7. Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 2002;23:87-96.
8. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139:26-32.
9. Trent JT, Kirsner RS, Romanelli P, Kerdel A. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch Dermatol 2003;139:39-43.
10. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockage of CD95 with human intravenous immunoglobulin. Science 1998;282:490-493.
11. Heggers JP, Ko F, Robson MC, Heggers R, Craft KE. Evaluation of burn blister fluid. Plast Reconstr Surg 1980;65: 798-804.
12. Shakespeare PG, Levock PL. Proteins in blister fluid. Burns 1978;4:254-260.
13. Imahara SD, Holmes JH IV, Heimbach DM, et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res 2006;27:270-275.
14. Oplatek A, Brown K, Sen S, Halerz M, Supple K, Gamelli RL. Long term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res 2006 27:26-33.
15. Mayorga C, Torre MJ, Corzo JL, et al. Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin. Ann Allergy Asthma Immunol 2003;9:86-91.
16. Rhodes LE, Hashim IA, McLaughlin PJ, Friedman PS. Blister fluid cytokines in cutaneous inflammatory bullous disorders. Acta Derm Venereol 1999;79:288-290.
17. Stella M, Cassano P, Bollero D, et al. Toxic epidermal necrolysis treated with intravenous high dose immunoglobulins: our experience. Dermatology 2001;203:45-49.
18. Al-Mutairi N, Arun J, Osama NE, et al. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol 2004;43:847-851.
19. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004;25:246-255.
20. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139:33-36.
21. Tan AW, Thong BY, Yip LW, Chung HH, Ng SK. High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. J Dermatol 2005;32:1-6.